Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 4.5% – What’s Next?

22 Jan 2026, 23:42 by Mitch Edgeman · The Markets Daily

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report)’s share price dropped 4.5% during trading on Thursday . The company traded as low as $16.25 and last traded at $16.1650. Approximately 1,109,476 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 2,037,642 shares. The stock had previously closed at $16.92.

Analyst Ratings Changes

AMLX has been the subject of several research reports. Bank of America increased their target price on shares of Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Monday, December 29th. HC Wainwright lifted their price target on shares of Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the company a “buy” rating in a report on Friday, November 7th. Wall Street Zen cut shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Finally, Citigroup boosted their target price on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $17.25.

View Our Latest Stock Report on AMLX

Amylyx Pharmaceuticals Stock Performance

The company has a market cap of $1.78 billion, a price-to-earnings ratio of -9.02 and a beta of -0.31. The firm’s 50-day moving average price is $13.26 and its 200 day moving average price is $11.79.

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. As a group, equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Insider Activity at Amylyx Pharmaceuticals

In other news, CFO James M. Frates sold 3,326 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $11.11, for a total value of $36,951.86. Following the completion of the sale, the chief financial officer directly owned 177,104 shares of the company’s stock, valued at $1,967,625.44. This represents a 1.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Justin B. Klee sold 1,995 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $13.89, for a total transaction of $27,710.55. Following the transaction, the chief executive officer owned 3,379,398 shares of the company’s stock, valued at approximately $46,939,838.22. This represents a 0.06% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 157,783 shares of company stock worth $2,122,808. 12.30% of the stock is owned by company insiders.

Institutional Trading of Amylyx Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. California State Teachers Retirement System bought a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at about $28,000. Ameritas Investment Partners Inc. bought a new position in Amylyx Pharmaceuticals in the second quarter valued at approximately $45,000. BNP Paribas Financial Markets increased its position in shares of Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after purchasing an additional 5,904 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth approximately $47,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Amylyx Pharmaceuticals during the 3rd quarter worth approximately $48,000. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

(Get Free Report)

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.